ReviewCureus2026
Beyond Glucose Control: A Comprehensive Review of Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors in Heart Failure, Chronic Kidney Disease, and Nonalcoholic Fatty Liver Disease.
Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sodium-glucose cotransporter 2 (SGLT2) inhibitors were first introduced to enhance glycemic control in type 2 diabetes mellitus (T2DM). However, a series of large-scale cardiovascular and renal outcomes trials have revealed their substantial benefits in reducing heart failure (HF) hospitalizations, slowing chronic kidney disease (CKD) progression, and improving cardiorenal outcomes, even among non-diabetic populations. Early studies further suggest potential benefits in non-alcoholic fatty liver disease (NAFLD). In this comprehensive review, we synthesize the mechanistic basis, landmark trials, real-world evidence, and emerging guidelines that position SGLT2 inhibitors as cornerstone therapies in the management of HF and CKD, with growing research in NAFLD. By highlighting key clinical outcomes, safety profiles, and cost-effectiveness considerations, we underscore how SGLT2 inhibitors transcend their original role in glucose regulation to provide multifaceted protection across the cardiorenal-metabolic spectrum.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.